EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
|
EQS-Ad-hoc: Redcare Pharmacy N.V. / Key word(s): Change in Forecast/Strategic Company Decision Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated. Sevenum, the Netherlands, 3 October 2024. The Management Board of Redcare Pharmacy has decided to intensify marketing investments for its e-Rx business in Germany in Q4 based on very convincing metrics, specifically the repeat order rate and average basket size. This decision is driven by the firm belief that the right investments now will result in further profitable growth and expansion of Redcare Pharmacy’s market leadership. The Management Board of Redcare Pharmacy has updated the full-year guidance for 2024 as follows:
Contact: rikutis consulting Thomas Schnorrenberg Cel: +49 151 46 53 13 17 E-Mail: presse@shop-apotheke.com End of Inside Information Information and Explanation of the Issuer to this announcement: A live conference call and webcast will be held on 4 October 2024 at 11h00 (CEST), followed by a Q&A session. The presentation is available for download on the Redcare Pharmacy website (https://ir.redcare-pharmacy.com/en/event-and-publication). Webcast link to the livestream: https://www.webcast-eqs.com/redcarepharmacy-2024-q3-tradingupdate Registration link for participants of the conference call:
03-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2001745 |
| End of Announcement | EQS News Service |
|
|
2001745 03-Oct-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 539,71 | 701,01 | 968,06 | 1.060,32 | 1.204,35 | 1.798,76 | 2.446,00 | |
| EBITDA1,2 | -15,56 | -18,58 | 15,20 | -38,73 | -29,66 | 39,99 | 81,00 | |
| EBITDA-Margin3 | -2,88 | -2,65 | 1,57 | -3,65 | -2,46 | 2,22 | 3,31 | |
| EBIT1,4 | -28,73 | -33,45 | -0,87 | -65,70 | -69,17 | -17,30 | 15,00 | |
| EBIT-Margin5 | -5,32 | -4,77 | -0,09 | -6,20 | -5,74 | -0,96 | 0,61 | |
| Net Profit (Loss)1 | -33,61 | -36,27 | -16,77 | -74,19 | -77,65 | -11,61 | 11,80 | |
| Net-Margin6 | -6,23 | -5,17 | -1,73 | -7,00 | -6,45 | -0,65 | 0,48 | |
| Cashflow1,7 | -23,54 | -30,37 | 17,80 | 11,64 | -29,11 | 61,46 | 0,00 | |
| Earnings per share8 | -2,79 | -2,78 | -1,17 | -4,15 | -4,32 | -0,73 | 0,50 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Redcare Pharmacy | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2AR94 | NL0012044747 | N.V. | 2.762,51 Mio € | 13.10.2016 | Halten | 9F3893WC+F5 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 75,44 | 0,00 | 0,00 | -65,04 | 5,29 | 44,95 | 1,54 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.05.2025 | 06.05.2025 | 29.07.2025 | 05.11.2024 | 11.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,60% | +1,60% | +3,66% | +5,85% | +385,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
